A detailed history of Jpmorgan Chase & CO transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 31,117 shares of KROS stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,117
Previous 30,695 1.37%
Holding current value
$1.79 Million
Previous $1.4 Million 28.82%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$41.68 - $58.07 $17,588 - $24,505
422 Added 1.37%
31,117 $1.81 Million
Q2 2024

Aug 12, 2024

SELL
$44.58 - $66.89 $1.1 Million - $1.65 Million
-24,715 Reduced 44.6%
30,695 $1.4 Million
Q1 2024

May 10, 2024

SELL
$41.26 - $70.48 $298,474 - $509,852
-7,234 Reduced 11.55%
55,410 $3.67 Million
Q4 2023

Feb 12, 2024

BUY
$27.12 - $41.05 $259,674 - $393,053
9,575 Added 18.04%
62,644 $2.49 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $738,075 - $1.01 Million
23,379 Added 78.74%
53,069 $1.69 Million
Q2 2023

Aug 11, 2023

BUY
$37.26 - $51.01 $233,620 - $319,832
6,270 Added 26.77%
29,690 $1.19 Million
Q1 2023

May 18, 2023

BUY
$41.44 - $59.32 $962,941 - $1.38 Million
23,237 Added 12697.81%
23,420 $1 Million
Q1 2023

May 11, 2023

SELL
$41.44 - $59.32 $1.71 Million - $2.45 Million
-41,298 Reduced 99.56%
183 $7,000
Q4 2022

Feb 13, 2023

BUY
$39.45 - $51.77 $935,359 - $1.23 Million
23,710 Added 133.42%
41,481 $1.99 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $70,806 - $102,185
2,547 Added 16.73%
17,771 $669,000
Q2 2022

Aug 11, 2022

SELL
$26.03 - $67.04 $580,573 - $1.5 Million
-22,304 Reduced 59.43%
15,224 $420,000
Q1 2022

May 11, 2022

BUY
$42.12 - $59.36 $182,337 - $256,969
4,329 Added 13.04%
37,528 $2.04 Million
Q4 2021

Feb 10, 2022

BUY
$36.95 - $62.89 $838,654 - $1.43 Million
22,697 Added 216.12%
33,199 $1.94 Million
Q3 2021

Nov 12, 2021

BUY
$29.27 - $43.71 $307,393 - $459,042
10,502 New
10,502 $415,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.48B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.